topotecan has been researched along with Osteosarcoma in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Buchdunger, E; Germain, GS; Harwood, FC; Houghton, PJ; Schuetz, JD; Stewart, CF; Traxler, P | 1 |
| Abbinanti, S; Agulnik, M; Attia, S; Cehic, R; Charlson, J; Helenowski, I; Hirbe, AC; Milhem, M; Mohindra, N; Monga, V; Okuno, S; Oppelt, P; Robinson, S; Schulte, B; Van Tine, BA | 1 |
| Bohr, VA; Christmann, M; Gestrich, C; Kaina, B; Roos, WP; Tomicic, MT | 1 |
| Baruchel, S; Kerbel, RS; Kumar, S; Man, S; Mokhtari, RB; Oliveira, ID; Sheikh, R; Wu, B; Xu, P; Yeger, H; Zhang, L | 1 |
| Breitfeld, PP; Chen, Z; Drachtman, R; Greffe, B; Healey, J; Krailo, M; Meyers, PA; Nachman, J; Nadel, H; Reaman, GH; Sato, JK; Seibel, NL | 1 |
| Adamson, PC; Balis, FM; Berg, SL; Blaney, SM; Bleyer, WA; Gillespie, A; Krailo, MD; Needle, MN; Poplack, DG; Reaman, GH; Sato, JK | 1 |
| Bernstein, ML; Harris, MB; Hayashi, R; Kepner, JL; Saylors, RL; Stine, KC; Sullivan, J; Vietti , TJ; Wall, DA | 1 |
| Duan, Z; Kronish, KM; Lamendola, DE; Penson, RT; Seiden, MV | 1 |
| Cheshire, PJ; Houghton, JA; Houghton, PJ; Myers, L; Stewart, CF; Synold, TW | 1 |
4 trial(s) available for topotecan and Osteosarcoma
| Article | Year |
|---|---|
Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Osteosarcoma; Prospective Studies; Pyrimidines; Sarcoma; Sulfonamides; Topotecan; Treatment Outcome; Young Adult | 2021 |
Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: children's Cancer Group (CCG) 7943.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Female; Humans; Lung Neoplasms; Maximum Tolerated Dose; Osteosarcoma; Prognosis; Survival Analysis; Survival Rate; Topotecan | 2007 |
Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Neoplasms; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infant; Infusions, Intravenous; Male; Neoplasms; Neuroblastoma; Neuroectodermal Tumors, Primitive, Peripheral; Osteosarcoma; Rhabdomyosarcoma; Sarcoma, Ewing; Soft Tissue Neoplasms; Topotecan | 1998 |
Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cyclophosphamide; Female; Humans; Infant; Infusions, Intravenous; Male; Neoplasm Recurrence, Local; Neoplasms; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Sarcoma, Ewing; Topotecan | 2001 |
5 other study(ies) available for topotecan and Osteosarcoma
| Article | Year |
|---|---|
Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Bone Neoplasms; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Irinotecan; Neoplasm Proteins; Osteosarcoma; Piperazines; Pyrimidines; Topotecan | 2004 |
WRN protects against topo I but not topo II inhibitors by preventing DNA break formation.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Bone Neoplasms; Bromodeoxyuridine; Cell Cycle; Cell Survival; Colony-Forming Units Assay; DNA Breaks; DNA Repair; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Enzyme Inhibitors; Etoposide; Exodeoxyribonucleases; Histones; Humans; Osteosarcoma; RecQ Helicases; RNA, Small Interfering; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured; Werner Syndrome Helicase | 2008 |
Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
Topics: Administration, Metronomic; Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Endothelial Cells; Humans; Indazoles; Mice; Mice, Inbred NOD; Mice, SCID; Microvessels; Neoplasms; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Neuroblastoma; Osteosarcoma; Pyrimidines; Random Allocation; Rhabdomyosarcoma; Stem Cells; Sulfonamides; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays | 2011 |
Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Northern; Blotting, Western; Caspase 3; Caspases; Cell Division; DNA, Complementary; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme-Linked Immunosorbent Assay; Genetic Vectors; Humans; Interleukin-6; Interleukin-8; Mitoxantrone; Osteosarcoma; Paclitaxel; Phenotype; RNA; Tetrazolium Salts; Thiazoles; Time Factors; Topotecan; Transfection; Tumor Cells, Cultured | 2002 |
Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
Topics: Adenocarcinoma; Adult; Animals; Antineoplastic Agents; Camptothecin; Child; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Humans; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Osteosarcoma; Remission Induction; Rhabdomyosarcoma; Time Factors; Topotecan; Tumor Cells, Cultured | 1992 |